Claudene George1, Joe Verghese2. 1. Division of Geriatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 2. Division of Cognitive and Motor Aging and Geriatrics, Albert Einstein College of Medicine, Bronx, New York.
Abstract
OBJECTIVES: To examine the relationship between polypharmacy and gait performance during simple (normal walk (NW)) and complex (walking while talking (WWT)) locomotion. DESIGN: Cross-sectional. SETTING: Community. PARTICIPANTS: Community-dwelling older adults (N = 482). MEASUREMENTS: Polypharmacy, defined as use of five or more medications and a cohort-specific alternate definition of eight or more medications, was examined. Velocity (cm/s) measured quantitatively during NW and WWT conditions. RESULTS: The 164 participants (34%) with polypharmacy of five or more medications were older (77.0 ± 6.6 vs 76.0 ± 6.4) and more likely to have hypertension, congestive heart failure, diabetes mellitus, myocardial infarction, and higher body mass index (BMI) and to have fallen within the last year than the remaining 318 without polypharmacy and walked 6 cm/s slower (P = .004) during NW and 4 cm/s slower during WWT (P = .07), adjusting for age, sex, and education. Group differences were not statistically significant after adjusting for comorbidities. Prevalence of polypharmacy of eight or more medications was 10%. This group walked 11 cm/s slower during NW (P < .001) and 8.6 cm/s slower during WWT (P = .01) than those without polypharmacy, adjusted for age, sex, and education. Participants taking eight or more medications had slower NW (8.5 cm/s; P = .01), and WWT (6.9 cm/s; P = .07), compared to those without polypharmacy, adjusting for comorbidities. Adjustments for BMI, high-risk drugs, falls, and comorbidities yielded slower NW (9.4 cm/s, P = .005) and WWT (7.9 cm/s, P = .04 among those with polypharmacy compared to those without polypharmacy). CONCLUSION: These results suggest an association between polypharmacy and locomotion that medical comorbidities only partly explained.
OBJECTIVES: To examine the relationship between polypharmacy and gait performance during simple (normal walk (NW)) and complex (walking while talking (WWT)) locomotion. DESIGN: Cross-sectional. SETTING: Community. PARTICIPANTS: Community-dwelling older adults (N = 482). MEASUREMENTS: Polypharmacy, defined as use of five or more medications and a cohort-specific alternate definition of eight or more medications, was examined. Velocity (cm/s) measured quantitatively during NW and WWT conditions. RESULTS: The 164 participants (34%) with polypharmacy of five or more medications were older (77.0 ± 6.6 vs 76.0 ± 6.4) and more likely to have hypertension, congestive heart failure, diabetes mellitus, myocardial infarction, and higher body mass index (BMI) and to have fallen within the last year than the remaining 318 without polypharmacy and walked 6 cm/s slower (P = .004) during NW and 4 cm/s slower during WWT (P = .07), adjusting for age, sex, and education. Group differences were not statistically significant after adjusting for comorbidities. Prevalence of polypharmacy of eight or more medications was 10%. This group walked 11 cm/s slower during NW (P < .001) and 8.6 cm/s slower during WWT (P = .01) than those without polypharmacy, adjusted for age, sex, and education. Participants taking eight or more medications had slower NW (8.5 cm/s; P = .01), and WWT (6.9 cm/s; P = .07), compared to those without polypharmacy, adjusting for comorbidities. Adjustments for BMI, high-risk drugs, falls, and comorbidities yielded slower NW (9.4 cm/s, P = .005) and WWT (7.9 cm/s, P = .04 among those with polypharmacy compared to those without polypharmacy). CONCLUSION: These results suggest an association between polypharmacy and locomotion that medical comorbidities only partly explained.
Authors: Joe Verghese; Herman Buschke; Lisa Viola; Mindy Katz; Charles Hall; Gail Kuslansky; Richard Lipton Journal: J Am Geriatr Soc Date: 2002-09 Impact factor: 5.562
Authors: F Sganga; D L Vetrano; S Volpato; A Cherubini; C Ruggiero; A Corsonello; P Fabbietti; F Lattanzio; R Bernabei; G Onder Journal: J Nutr Health Aging Date: 2014 Impact factor: 4.075
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: Johanna Jyrkkä; Hannes Enlund; Piia Lavikainen; Raimo Sulkava; Sirpa Hartikainen Journal: Pharmacoepidemiol Drug Saf Date: 2011-02-09 Impact factor: 2.890
Authors: John C Woolcott; Kathryn J Richardson; Matthew O Wiens; Bhavini Patel; Judith Marin; Karim M Khan; Carlo A Marra Journal: Arch Intern Med Date: 2009-11-23
Authors: Mariann M Gabrawy; Sarah Campbell; Mary Anna Carbone; Tatiana V Morozova; Gunjan H Arya; Lavanya B Turlapati; Jeremy D Walston; Michelle Starz-Gaiano; Logan Everett; Trudy F C Mackay; Jeff Leips; Peter M Abadir Journal: J Gerontol A Biol Sci Med Sci Date: 2019-11-13 Impact factor: 6.053
Authors: Joanna L Stollings; Sarah L Bloom; Li Wang; E Wesley Ely; James C Jackson; Carla M Sevin Journal: Ann Pharmacother Date: 2018-02-18 Impact factor: 3.154
Authors: Kathleen M Akgün; Supriya Krishnan; Shelli L Feder; Janet Tate; Jean S Kutner; Kristina Crothers Journal: Am J Hosp Palliat Care Date: 2019-09-24 Impact factor: 2.500
Authors: Caroline Krüger; Ingmar Schäfer; Hendrik van den Bussche; Michael Baehr; Horst Bickel; Angela Fuchs; Jochen Gensichen; Wolfgang Maier; Steffi G Riedel-Heller; Hans-Helmut König; Anne Dahlhaus; Gerhard Schön; Siegfried Weyerer; Birgitt Wiese; Wolfgang von Renteln-Kruse; Claudia Langebrake; Martin Scherer Journal: Eur J Gen Pract Date: 2021-12 Impact factor: 1.904